| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 4
The influence of prolactin-releasing prokinetic drugs on bone microarchitecture and biomechanics in streptozotocin-diabetic rat
1 Eskisehir Osmangazi University, Faculty of Medicine, Department of Physiology, Eskisehir, Türkiye2 Aydin Adnan Menderes University, Faculty of Veterinary Medicine, Department of Pathology, Aydin, Türkiye
3 Aydin Adnan Menderes University, Faculty of Veterinary Medicine, Department of Anatomy, Aydin, Türkiye
4 Aydin Adnan Menderes University, Faculty of Medicine, Department of Medical Pharmacology, Aydin, Türkiye
DOI : 10.23893/1307-2080.APS6354 Viewed : 1808 - Downloaded : 671 To understand the potential impact of antidopaminergics such as Domperidone (DOM), Metoclopramide (MCP), and Trimethobenzamide (TMB) used in diabetic gastroparesis, this study examined their effects?both harmful and beneficial?on bone fragility. A diabetic model was created in male Wistar rats by a single intraperitoneal injection of Streptozotocin (STZ, 60 mg/kg). Our groups consisted of: Control (no diabetes or treatment), STZ (diabetes) group, STZ+DOM (diabetes with DOM) group, STZ+MCP (diabetes with MCP) group, and STZ+TMB (diabetes with TMB) group. Treatments were administered daily during the last 2 weeks of the 8-week study. Bone biomechanical properties were evaluated using a three-point bending test (TPBT), while histopathological analysis and serum receptor activator of nuclear factor kappa-B ligand (RANKL) levels were also assessed. TPBT results indicated increased bone loss in the STZ group, and histological analysis revealed elevated lipid content in the femoral metaphysis. Rats in the STZ group showed significant alterations in bone biomechanical and histological parameters. Our study suggests that inducing diabetes with STZ in rats leads to bone loss within eight weeks, which may be valuable for testing new drugs aimed at treating osteoporosis in diabetic patients. Except for the doubling of RANKL levels with TMB among prolactin-releasing anti-dopaminergic agents in diabetic rats, these agents had no significant effect on bone mineral density or microarchitecture. Therefore, their use can be considered safe in sensitive diabetic populations. Keywords : antidopaminergic drugs, diabetic gastroparesis, rational drug therapy, seconder osteoporosis, streptozocin